423P From clinical trial to bedside: Triplet chemotherapy (FOLFOXIRI-B) in metastatic colorectal cancer
Guus M. Bol(Johns Hopkins University), Miriam Koopman(Utrecht University), Ilva Scheerman(University Medical Center Utrecht), TE Buffart(The Netherlands Cancer Institute), Sietske C. van Nassau(Utrecht University), V.E.P.P. Lemmens(Netherlands Comprehensive Cancer Organisation), Jesper van Breeschoten(Amsterdam University Medical Centers), Leonie J. Mekenkamp(Radboud University Nijmegen), Rob Kessels(The Netherlands Cancer Institute), Marinde J. G. Bond(Utrecht University), Henk M.W. Verheul(Erasmus MC Cancer Institute), Liselot Valkenburg‐van Iersel
Cited by 0
Related Papers
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|788
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
|British Journal of Cancer|2009|518
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
|Nature reviews. Cancer|2007|502
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
|Angiogenesis|2009|488